Barclays raised the firm’s price target on PTC Therapeutics to $31 from $25 and keeps an Equal Weight rating on the shares following the “beat and raise” Q2. Total revenue beat estimates, driven by Evrysdi royalty, and PTC’s pipeline programs were on track, with multiple regulatory updates expected in 2024, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Q2 Financial Performance and Updates Webinar
- PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Is PTCT a Buy, Before Earnings?
- PTC Therapeutics submits sepiapterin NDA to U.S. FDA
- Truist healthcare analyst holds an analyst/industry conference call